When was Epibone founded?

Epibone was founded in 2013 and raised its 1st funding round 1 year after it was founded.

Where is Epibone located?

Epibone is headquartered in Brooklyn, United States.

Who is the current CEO of Epibone?

Nina Tandon of Epibone. They have also founded 1 company.

How many employees does Epibone have?

As of Aug 31, 2026, the latest employee count at Epibone is 23.

Is Epibone a funded company?

Epibone is a funded company, having raised a total of $48.6M across 10 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on Jun 11, 2014.

When was the latest funding round of Epibone?

Epibone's latest funding was a $***** Series B round on Sep 02, 2025, with participation from 0 investor.

Where does Epibone rank among its competitors?

Epibone ranks 22nd amongst 213 active competitors, of which 59 are funded. It stands 8th in terms of total funding among its competitors. The most recent competitor to raise funding was Theradaptive, which secured $36.2M in Jul, 2026.

Who are the top competitors of Epibone?

Epibone's top competitors include Humacyte, AxoGen and Ossio. Among them, Theradaptive secured the most recent funding round in July, 2026.

Epibone - 2026 Company Profile, Team, Funding & Competitors

Epibone is a series B company based in Brooklyn (United States), founded in 2013 by Gordana Vunjak Novakovic, Sarindr Bhumiratana, Sidney Eisig, Elisa Cimetta and Nina Tandon. It operates as a Developer of patient‑specific bone and cartilage grafts. Epibone has raised $48.6M in funding from Kendall Capital Partners. The company has 213 active competitors, including 59 funded and 64 that have exited. Its top competitors include companies like Humacyte, AxoGen and Ossio.

Company Details

Developer of patient‑specific bone and cartilage grafts. The company is offering custom‑shaped, living bone grafts engineered from a patient’s adipose‑derived mesenchymal stem cells and a CT scan of the defect. These are intended for complex bone‑reconstruction cases such as facial, craniofacial, or other skeletal defects.

Website: www.epibone.com/
Social
Email ID: *****@epibone.com

Key Metrics

Founded Year

2013

Location

Brooklyn, United States

Stage

Series B

Total Funding

$48.6M in 10 rounds

Latest Funding Round

Series B, Sep 02, 2025, $*****

Investors

Kendall Capital Partners & 26 more

Ranked

22^nd among 213 active competitors

Employee Count

23 as on Aug 31, 2026

Similar Companies

Humacyte & 269 more

View Epibone's full profile

Epibone is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
EPIBONE, INC. CIN: 5368940 , United States, Active	Jul 02, 2018	-	-	-

Epibone has raised a total funding of $48.6M over 10 rounds. Its first funding round was on Jun 11, 2014. Epibone has 27 institutional investors.

Here is the list of recent funding rounds of Epibone:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Sep 02, 2025	4356286	Series B	7334433	2220036	1093359	2361863
Nov 08, 2024	3950821	Series B	7530313	6334779	4043943	LifeSpan Vision Ventures & 1 more
Dec 12, 2022	9093093	Series B	7895362	2738199	7184563	5864158

Access funding benchmarks and valuations. Sign up today!

View details of Epibone's funding rounds and investors

The founders of Epibone are Gordana Vunjak Novakovic, Sarindr Bhumiratana, Sidney Eisig, Elisa Cimetta and Nina Tandon. Nina Tandon is the CEO of Epibone.

Here are the details of Epibone's key team members:

Gordana Vunjak Novakovic: Co-Founder of Epibone and founder of 1 other company.
Sarindr Bhumiratana: Co-Founder & CSO of Epibone.
Contact Info: 1 email address
Sidney Eisig: Co-Founder of Epibone.
Elisa Cimetta: Co-Founder of Epibone.
Nina Tandon: Co-Founder & CEO of Epibone.
Contact Info: 1 email address

View details of Epibone's Founder profiles and Board Members

Epibone's employee count trend

Epibone has 23 employees as of Aug 26. Here is Epibone's employee count trend over the years:

Uncover Epibone's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Epibone include Humacyte, AxoGen and Ossio. Here is the list of Top 10 competitors of Epibone, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Humacyte 2004, Durham (United States), Public	Provider of human tissue-based products for vascular disease	$425M	Access Industries, Fresenius Medical Care ... & 15 others	66/100
2nd	AxoGen 2002, Alachua (United States), Public	Developer of therapies for the repair of peripheral nerve injuries	$62.4M	Oberland Capital, Cardinal Partners & 10 others	65/100
3rd	Ossio 2014, Caesarea (Israel), Series C	Bone regeneration biocomposite	$89M	MVM, Questa Capital & 7 others	64/100
4th	CUTISS 2017, Zurich (Switzerland), Series C	Company developing personalized skin tissue therapeutics for skin defect treatments	$157M	Cherry Bay Capital Group, Rode Kruis Ziekenhuis ... & 15 others	63/100
5th	RevBio 2014, Lowell (United States), Series B	Developer of synthetic adhesive used for bone/dental repair	$27.5M	Pacific Dental Services, The JHA Capital & 4 others	63/100
6th	Neurona Therapeutics 2008, San Francisco (United States), Acquired	Developer of cell-based therapies to treat intractable neurological diseases	$418M	The Column Group, Cormorant Asset Management ... & 15 others	62/100
7th	Vericel Corporation 1989, Cambridge (United States), Public	Developer of autologous stem cell therapies	$40M	Eastern Capital, Ignite 500 & 2 others	62/100
8th	Theradaptive 2004, Boston (United States), Series B	Developer of protein engineering technology creating targeted therapeutics for tissue repair	$50M	TEDCO, Defense.gov & 4 others	61/100
9th	MiMedx Group 1985, Marietta (United States), Public	Regenerative biomaterial products and bioimplants for wound, surgical, sports medicine and orthopedics	-	Hayfin, Trelys & 4 others	61/100
10th	Gamida Cell 1998, Jerusalem (Israel), Public	Developer of cell therapies to treat cancer and other serious diseases	$139M	Shavit Capital, Auriga Partners & 14 others	61/100
22nd	Epibone 2013, Brooklyn (United States), Series B	Developer of patient‑specific bone and cartilage grafts	$48.6M	Hyperspeed, Partnership for New York City ... & 25 others	51/100